Dentsply Sirona Q2 non-GAAP EPS up 10%; 2019 guidance raised

Dentsply Sirona (XRAY) Q2 results: Revenues: $1,009.4M (-3.1%); Technologies & Equipment: $558.4M (+0.9%); Consumables: $451M (-7.8%).

Net Income: $36.4M (+103.2%); EPS: $0.16 (+103.2%); Non-GAAP Net Income: $147.9M (+8.1%); Non-GAAP EPS: $0.66 (+10.0%); CF Ops: $145.1M.

2019 Guidance: Non-GAAP EPS: $2.35 – 2.45 from $2.30 – 2.40.

Previously: DENTSPLY SIRONA EPS beats by $0.03, misses on revenue (Aug. 2)

https://seekingalpha.com/news/3485988-dentsply-sirona-q2-non-gaap-eps-10-percent-2019-guidance-raised

Premarket analyst action

Stericycle (NASDAQ:SRCL) upgraded to Neutral with a $44 (flat) price target at Baird.

Myriad Genetics (NASDAQ:MYGN) upgraded to Neutral with a $46 (2% upside) price target at BofA Merrill Lynch. Shares down 2% premarket.

Ultragenyx (NASDAQ:RARE) resumed with Outperform rating and $75 (24% upside) price target at Wedbush.

Abiomed (NASDAQ:ABMD) downgraded to Equal Weight with a $215 (5% upside) price target at Morgan Stanley. Downgraded to Neutral at Guggenheim.

Adaptimmune (NASDAQ:ADAP) downgraded to Neutral at Guggenheim.

Biotelemetry (NASDAQ:BEAT) downgraded to Market Perform at Raymond James.

Clovis Oncology (NASDAQ:CLVS) downgraded to Neutral at Guggenheim.

Intersect ENT (NASDAQ:XENT) downgraded to Neutral at Guggenheim. Downgraded to Neutral with a $17 (16% downside risk) price target at Piper Jaffray.

Mirati Therapeutics (NASDAQ:MRTX) downgraded to Underweight with an $85 (19% downside risk) price target at JPMorgan.

https://seekingalpha.com/news/3486059-guggenheim-softens-view-four-biotechs-premarket-analyst-action

Deciphera Pharmaceuticals EPS beats by $0.53, beats on revenue

Deciphera Pharmaceuticals (NASDAQ:DCPH): Q2 GAAP EPS of -$0.56 beats by $0.53.

Revenue of $25M beats by $22.78M.

Press Release

https://seekingalpha.com/news/3486066-deciphera-pharmaceuticals-eps-beats-0_53-beats-revenue

Stemline up 3% premarket on Q2 beat

Stemline Therapeutics (STML) Q2 results: Elzonris sales: $13M.

Net Loss: ($16.8M) (+11.1%); Loss Per Share: ($0.42) (+36.4%); Quick Assets: $103.9M (+72.9%).

Shares are up 3% premarket.

Previously: Stemline Therapeutics EPS beats by $0.14, beats on revenue(Aug. 2)

https://seekingalpha.com/news/3486080-stemline-3-percent-premarket-q2-beat

Harrow Health nabs rights to microbial agent for eye and ear infections

Harrow Health (NASDAQ:HROW) subsidiary Stowe Pharmaceuticals in-licenses worldwide rights to TGV Health’s antimicrobial agent Zian for complex bacterial, fungal and viral infections in the eye and ear. The initial primary indication will be adenoviral conjunctivitis. Secondary indications include mixed bacterial-viral infections, keratitis, endophthalmitis and corneal ulcers.

Financial terms are not disclosed.

https://seekingalpha.com/news/3486094-harrow-health-nabs-rights-microbial-agent-eye-ear-infections

Regional Health sells 3 properties, extinguishes debt; up 55% premarket

Thinly traded nano cap Regional Health Properties (NYSEMKT:RHE) is up 55% premarket on light volume on the heels of its sale of three skilled nursing facilities to affiliates of MED Healthcare Partners LLC for $26.1M in cash. A fourth property will be sold by August 28.

RHE used the proceeds to repay $24.7M in debt secured by the four facilities.

https://seekingalpha.com/news/3486134-regional-health-sells-three-properties-extinguishes-debt-shares-55-percent-premarket

Momenta misses Q3 consensus

Momenta Pharmaceuticals (MNTA) Q3 results: Revenues: $5.2M (-60.0%); Product revenue: $3.3M (-72.0%); R&D revenue: $1.8M (+38.5%).

Net Loss: ($114M) (-62.9%); Loss Per Share: ($1.16) (-27.5%); Quick Assets: $344.1M (-23.4%).

The Company launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), with top-line data expected by end of 2021.

Momenta also received FDA Fast Track Designation for nipocalimab in wAIHA and hemolytic disease of the fetus and newborn.

Previously: Momenta Pharmaceuticals EPS misses by $0.73, misses on revenue (Aug. 2)

Momenta Pharmaceuticals (MNTA) Q3 results: Revenues: $5.2M (-60.0%); Product revenue: $3.3M (-72.0%); R&D revenue: $1.8M (+38.5%).

Net Loss: ($114M) (-62.9%); Loss Per Share: ($1.16) (-27.5%); Quick Assets: $344.1M (-23.4%).

The Company launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), with top-line data expected by end of 2021.

Momenta also received FDA Fast Track Designation for nipocalimab in wAIHA and hemolytic disease of the fetus and newborn.

Previously: Momenta Pharmaceuticals EPS misses by $0.73, misses on revenue (Aug. 2)